<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39333651</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>27</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>The impact of host microRNAs on the development of conserved mutations of SARS-CoV-2.</ArticleTitle><Pagination><StartPage>22091</StartPage><MedlinePgn>22091</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">22091</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-70974-7</ELocationID><Abstract><AbstractText>SARS-CoV-2, the virus responsible for the COVID-19 pandemic, has undergone various genetic alterations due to evolutionary pressures exerted by host cells, including intracellular antiviral mechanisms such as targeting by human microRNAs (miRNAs). This study investigates the impact of miRNAs hsa-miR-3132 and hsa-miR-4650 on the viral genome. Sequence alignment revealed conserved mutations in the binding sites of these miRNAs in adapted strains compared to the original Wuhan-Hu-1 strain, leading to their deletion. Despite modest expression of these miRNAs in SARS-CoV-2 target tissues, their efficacy against mutant strains is reduced due to the loss of binding sites. Structural analysis indicates that the mutant genome is more stable than the Wuhan-Hu-1 genome. Luciferase and virus titration assays demonstrate that hsa-miR-3132 and hsa-miR-4650 effectively target the Nsp3 gene in the Wuhan-Hu-1 strain but not in mutant strains lacking their binding sites. These findings suggest that the observed mutations help the virus evade selective pressure from human miRNAs, contributing to its adaptation.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ghaemi</LastName><ForeName>Shokoofeh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Microbiology, School of Biology, College of Science, University of Tehran, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdoli</LastName><ForeName>Asghar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amirabad Virology Laboratory, Vaccine Unit, Tehran, 1413693341, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karimi</LastName><ForeName>Hesam</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saadatpour</LastName><ForeName>Fatemeh</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Microbiology, School of Biology, College of Science, University of Tehran, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arefian</LastName><ForeName>Ehsan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Microbiology, School of Biology, College of Science, University of Tehran, Tehran, Iran. arefian@ut.ac.ir.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stem Cells Technology and Tissue Regeneration Department, School of Biology, College of Science, University of Tehran, Tehran, Iran. arefian@ut.ac.ir.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>99019844</GrantID><Agency>Iran National Science Foundation</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="Y">MicroRNAs</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016679" MajorTopicYN="Y">Genome, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Conserved mutation</Keyword><Keyword MajorTopicYN="N">Has-miR-3132</Keyword><Keyword MajorTopicYN="N">Has-miR-4650</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>9</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>23</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39333651</ArticleId><ArticleId IdType="pmc">PMC11437047</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-70974-7</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-70974-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wang, N. et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res.23(8), 986–993 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3731569</ArticleId><ArticleId IdType="pubmed">23835475</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali Hosseini Rad, S. M. &amp; McLellan, A. D. Implications of sars-cov-2 mutations for genomic rna structure and host microrna targeting. Int. J. Mol. Sci.21(13), 1–18 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7370282</ArticleId><ArticleId IdType="pubmed">32645951</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng, Q. et al. Roles of host small RNAs in the evolution and host tropism of coronaviruses. Brief Bioinform.22(2), 1096–1105 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7929378</ArticleId><ArticleId IdType="pubmed">33587745</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding, S. W. &amp; Voinnet, O. Antiviral immunity directed by small RNAs. Cell.130(3), 413–426 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2703654</ArticleId><ArticleId IdType="pubmed">17693253</ArticleId></ArticleIdList></Reference><Reference><Citation>Maillard, P. V., van der Veen, A. G., Poirier, E. Z. &amp; Reis-Sousa, C. Slicing and dicing viruses: Antiviral RNA interference in mammals. EMBO J.38(8), 1–13 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6463209</ArticleId><ArticleId IdType="pubmed">30872283</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo, Z., Li, Y. &amp; Ding, S. W. Small RNA-based antimicrobial immunity. Nat. Rev. Immunol.19(1), 31–44. 10.1038/s41577-018-0071-x (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30301972</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, Y., Lu, J., Han, Y., Fan, X. &amp; Ding, S. W. RNA interference functions as an antiviral immunity mechanism in mammals. Science (80-).342(6155), 231–4 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3875315</ArticleId><ArticleId IdType="pubmed">24115437</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghildiyal, M. &amp; Zamore, P. D. Small silencing RNAs: An expanding universe. Nat. Rev. Genet.10(2), 94–108 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2724769</ArticleId><ArticleId IdType="pubmed">19148191</ArticleId></ArticleIdList></Reference><Reference><Citation>Berkhout, B. RNAi-mediated antiviral immunity in mammals. Curr. Opin. Virol.32, 9–14. 10.1016/j.coviro.2018.07.008 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30015014</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis, B. P., Burge, C. B. &amp; Bartel, D. P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell.120(1), 15–20 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15652477</ArticleId></ArticleIdList></Reference><Reference><Citation>Jopling, C. L., Norman, K. L. &amp; Sarnow, P. Positive and negative modulation of viral and cellular mRNAs by liver-specific MicroRNA miR-122. Cold Spring Harb Symp. Quant. Biol.71, 369–376 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17381319</ArticleId></ArticleIdList></Reference><Reference><Citation>Lecellier, C. H. et al. A cellular microRNA mediates antiviral defense in human cells. Science (80-).308(5721), 557–60 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15845854</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, G. et al. Suppression of hepatitis B virus replication by microRNA-199a-3p and microRNA-210. Antiviral Res.88(2), 169–75. 10.1016/j.antiviral.2010.08.008 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20728471</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathans, R. et al. Cellular MicroRNA and P bodies modulate Host-HIV-1 interactions. Mol Cell.34(6), 696–709. 10.1016/j.molcel.2009.06.003 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763548</ArticleId><ArticleId IdType="pubmed">19560422</ArticleId></ArticleIdList></Reference><Reference><Citation>Arboleda, J. F., Fernandez, G. J. &amp; Urcuqui-Inchima, S. Vitamin D-mediated attenuation of miR-155 in human macrophages infected with dengue virus: Implications for the cytokine response. Infect. Genet. Evol.69, 12–21. 10.1016/j.meegid.2018.12.033 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30639520</ArticleId></ArticleIdList></Reference><Reference><Citation>Otsuka, M. et al. Hypersusceptibility to vesicular stomatitis virus infection in Dicer1-deficient mice is due to impaired miR24 and miR93 expression. Immunity.27(1), 123–134 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17613256</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho, B. C. et al. Enterovirus-induced miR-141 contributes to shutoff of host protein translation by targeting the translation initiation factor eIF4E. Cell Host Microbe.9(1), 58–69. 10.1016/j.chom.2010.12.001 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21238947</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues, D. V. S. et al. MicroRNAs in cell cycle progression and proliferation: Molecular mechanisms and pathways. Non-Coding RNA Investig.10.21037/ncri.2018.04.06 (2018).</Citation></Reference><Reference><Citation>Bruscella, P. et al. Viruses and miRNAs: More friends than foes. Front Microbiol.8(MAY), 1–11 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5430039</ArticleId><ArticleId IdType="pubmed">28555130</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan, M. A. A. K., Sany, M. R. U., Islam, M. S. &amp; Islam, A. B. M. M. K. Epigenetic regulator miRNA pattern differences among SARS-CoV, SARS-CoV-2, and SARS-CoV-2 world-wide isolates delineated the mystery behind the epic pathogenicity and distinct clinical characteristics of pandemic COVID-19. Front Genet.11, 765 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7381279</ArticleId><ArticleId IdType="pubmed">32765592</ArticleId></ArticleIdList></Reference><Reference><Citation>Abedi, F., Rezaee, R., Hayes, A. W., Nasiripour, S. &amp; Karimi, G. MicroRNAs and SARS-CoV-2 life cycle, pathogenesis, and mutations: biomarkers or therapeutic agents?. Cell Cycle.20(2), 143–53. 10.1080/15384101.2020.1867792 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7889196</ArticleId><ArticleId IdType="pubmed">33382348</ArticleId></ArticleIdList></Reference><Reference><Citation>Demirci, M. D. S. &amp; Adan, A. Computational analysis of microRNA-mediated interactions in SARS-CoV-2 infection. PeerJ.2020(6), 1–17 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7278893</ArticleId><ArticleId IdType="pubmed">32547891</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartel, D. P. Metazoan MicroRNAs. Cell.173(1), 20–51. 10.1016/j.cell.2018.03.006 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6091663</ArticleId><ArticleId IdType="pubmed">29570994</ArticleId></ArticleIdList></Reference><Reference><Citation>Krol, J., Loedige, I. &amp; Filipowicz, W. The widespread regulation of microRNA biogenesis, function and decay. Nat. Rev. Genet.11(9), 597–610. 10.1038/nrg2843 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20661255</ArticleId></ArticleIdList></Reference><Reference><Citation>Weissman, D. et al. D614G spike mutation increases SARS CoV-2 susceptibility to neutralization. Cell Host Microbe29(1), 23-31.e4 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7707640</ArticleId><ArticleId IdType="pubmed">33306985</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, Y., Liu, Q. &amp; Guo, D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol.92(4), 418–423 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7167049</ArticleId><ArticleId IdType="pubmed">31967327</ArticleId></ArticleIdList></Reference><Reference><Citation>Astuti, I. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response. Diabetes Metab. Syndr. Clin. Res. Rev.14(4), 407–12. 10.1016/j.dsx.2020.04.020 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7165108</ArticleId><ArticleId IdType="pubmed">32335367</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dorp, L. et al. No evidence for increased transmissibility from recurrent mutations in SARS-CoV-2. Nat Commun.11, 1. 10.1038/s41467-020-19818-2 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7688939</ArticleId><ArticleId IdType="pubmed">33239633</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogawa J, Zhu W, Tonnu N, Singer O, Hunter T, Ryan AL, et al. The D614G mutation in the SARS-CoV2 Spike protein increases infectivity in an ACE2 receptor dependent manner. bioRxiv Prepr Serv Biol. 2020; http://www.ncbi.nlm.nih.gov/pubmed/32743569http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC7386486</Citation></Reference><Reference><Citation>Korber, B. et al. Tracking changes in SARS-CoV-2 spike: Evidence that D614G increases infectivity of the COVID-19 virus. Cell.182(4), 812-827.e19 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7332439</ArticleId><ArticleId IdType="pubmed">32697968</ArticleId></ArticleIdList></Reference><Reference><Citation>Yurkovetskiy, L. et al. Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant. Cell.183(3), 739–751. 10.1016/j.cell.2020.09.032 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7492024</ArticleId><ArticleId IdType="pubmed">32991842</ArticleId></ArticleIdList></Reference><Reference><Citation>Benton, D. J. et al. The effect of the D614G substitution on the structure of the spike glycoprotein of SARS-CoV-2. Proc. Natl. Acad. Sci. USA118(9), 2–5 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7936381</ArticleId><ArticleId IdType="pubmed">33579792</ArticleId></ArticleIdList></Reference><Reference><Citation>Sen, D., Debnath, P., Debnath, B., Bhaumik, S. &amp; Debnath, S. Identification of potential inhibitors of SARS-CoV-2 main protease and spike receptor from 10 important spices through structure-based virtual screening and molecular dynamic study. J. Biomol. Struct. Dyn.40(2), 941–62. 10.1080/07391102.2020.1819883 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7544938</ArticleId><ArticleId IdType="pubmed">32948116</ArticleId></ArticleIdList></Reference><Reference><Citation>Koyama, T., Weeraratne, D., Snowdon, J. L. &amp; Parida, L. Emergence of drift variants that may affect covid-19 vaccine development and antibody treatment. Pathogens.9(5), 1–7 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7281497</ArticleId><ArticleId IdType="pubmed">32357545</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniloski Z, Guo X, Sanjana NE. The D614G mutation in SARS-CoV-2 Spike increases transduction of multiple human cell types. bioRxiv Prepr Serv Biol. 2020;1–16.</Citation></Reference><Reference><Citation>Mercatelli, D. &amp; Giorgi, F. M. Geographic and genomic distribution of SARS-CoV-2 mutations. Front. Microbiol.11(July), 1–13 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7387429</ArticleId><ArticleId IdType="pubmed">32793182</ArticleId></ArticleIdList></Reference><Reference><Citation>Koyama, T., Platt, D. &amp; Parida, L. Variant analysis of SARS-cov-2 genomes. Bull. World Health Organ.98(7), 495–504 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7375210</ArticleId><ArticleId IdType="pubmed">32742035</ArticleId></ArticleIdList></Reference><Reference><Citation>Faure, G., Ogurtsov, A. Y., Shabalina, S. A. &amp; Koonin, E. V. Role of mRNA structure in the control of protein folding. Nucleic Acids Res.44(22), 10898–10911 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5159526</ArticleId><ArticleId IdType="pubmed">27466388</ArticleId></ArticleIdList></Reference><Reference><Citation>Peeri, M. &amp; Tuller, T. High-resolution modeling of the selection on local mRNA folding strength in coding sequences across the tree of life. Genome Biol.21(1), 1–20 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7063772</ArticleId><ArticleId IdType="pubmed">32151272</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, L., Yang, C. S., Varelas, X. &amp; Monti, S. Altered RNA editing in 3′ UTR perturbs microRNA-mediated regulation of oncogenes and tumor-suppressors. Sci. Rep.6, C–13. 10.1038/srep23226 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4793219</ArticleId><ArticleId IdType="pubmed">26980570</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Dorp, L. et al. Infection, genetics and evolution emergence of genomic diversity and recurrent mutations in SARS-CoV-2. Infect Genet Evol.83, 104351. 10.1016/j.meegid.2020.104351 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7199730</ArticleId><ArticleId IdType="pubmed">32387564</ArticleId></ArticleIdList></Reference><Reference><Citation>Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, et al. Journal Pre-proof. 2020.</Citation></Reference><Reference><Citation>Mahajan VS, Drake A, Chen J. Virus-specific host miRNAs : Antiviral defenses or promoters of persistent infection ? 2008; 1–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2709239</ArticleId><ArticleId IdType="pubmed">19059006</ArticleId></ArticleIdList></Reference><Reference><Citation>Cullen, B. R. Viruses and microRNAs. Nat. Genet.38, 25–30 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16736021</ArticleId></ArticleIdList></Reference><Reference><Citation>Cullen, B. R. Five questions about viruses and MicroRNAs. PLoS Pathog.6(2), 2–4 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2829071</ArticleId><ArticleId IdType="pubmed">20195463</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly, E. J., Hadac, E. M., Greiner, S. &amp; Russell, S. J. Engineering microRNA responsiveness to decrease virus pathogenicity. Nat. Med.14(11), 1278–1283 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18953352</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez, J. T. et al. MicroRNA-mediated species-specific attenuation of influenza A virus. Nat. Biotechnol.27(6), 572–576 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19483680</ArticleId></ArticleIdList></Reference><Reference><Citation>Langlois, R. A. et al. MicroRNA-based strategy to mitigate the risk of gain-of-function influenza studies. Nat. Biotechnol.31(9), 844–848 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3808852</ArticleId><ArticleId IdType="pubmed">23934176</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes, D., Kunitomi, M., Vignuzzi, M., Saksela, K. &amp; Andino, R. Article harnessing endogenous miRNAs to control virus tissue tropism as a strategy for developing attenuated virus vaccines. Cell Host Microbe4, 239–248 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2605097</ArticleId><ArticleId IdType="pubmed">18779050</ArticleId></ArticleIdList></Reference><Reference><Citation>De Maio, N. et al. Mutation rates and selection on synonymous mutations in SARS-CoV-2. Genome Biol Evol.13(5), 1–14 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8135539</ArticleId><ArticleId IdType="pubmed">33895815</ArticleId></ArticleIdList></Reference><Reference><Citation>Shan, K. J., Wei, C., Wang, Y., Huan, Q. &amp; Qian, W. Host-specific asymmetric accumulation of mutation types reveals that the origin of SARS-CoV-2 is consistent with a natural process. Innovation.2(4), 100159 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8405235</ArticleId><ArticleId IdType="pubmed">34485968</ArticleId></ArticleIdList></Reference><Reference><Citation>de Sousa, M. C., Gjorgjieva, M., Dolicka, D., Sobolewski, C. &amp; Foti, M. Deciphering miRNAs’ action through miRNA editing. Int. J. Mol. Sci.20(24), 6249 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6941098</ArticleId><ArticleId IdType="pubmed">31835747</ArticleId></ArticleIdList></Reference><Reference><Citation>Rad, S. M. A. H., Wannigama, D. L., Hirankarn, N. &amp; McLellan, A. D. The impact of non-synonymous mutations on miRNA binding sites within the SARS-CoV-2 NSP3 and NSP4 genes. Sci Rep.13(1), 1–6. 10.1038/s41598-023-44219-y (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10560223</ArticleId><ArticleId IdType="pubmed">37805621</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuker, M. &amp; Stiegler, P. Information this paper presents a new computer method for folding an RNA molecule. Nucleic Acids Res.9(11981), 133–48 (1980).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC326673</ArticleId><ArticleId IdType="pubmed">6163133</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding, Y. E., Chan, C. &amp; Lawrence, C. E. Bioinformatics RNA secondary structure prediction by centroids in a Boltzmann weighted ensemble. RNA11, 1157–66 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1370799</ArticleId><ArticleId IdType="pubmed">16043502</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabarinathan, R. et al. RNAsnp: Efficient detection of local RNA secondary structure changes induced by SNPs. Hum. Mutat.34, 546–556 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3708107</ArticleId><ArticleId IdType="pubmed">23315997</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni, W. et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit. Care24, 1–10 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7356137</ArticleId><ArticleId IdType="pubmed">32660650</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludwig, N. et al. Distribution of miRNA expression across human tissues. Nucleic Acids Res.44, 3865–3877 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4856985</ArticleId><ArticleId IdType="pubmed">26921406</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmieri, V. et al. IMOTA: An interactive multi-omics tissue atlas for the analysis of human miRNA—Target interactions. Nucleic Acids Res.46, D770–D775 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5753248</ArticleId><ArticleId IdType="pubmed">28977416</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos, A., Tsafou, K. &amp; Stolte, C. Comprehensive comparison of large-scale tissue expression datasets. PeerJ3, e1054 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4493645</ArticleId><ArticleId IdType="pubmed">26157623</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramachandran, K. et al. Human miRNome profiling identifies MicroRNAs differentially present in the urine after kidney injury. Clin Chem.59, 1742–1752 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3870155</ArticleId><ArticleId IdType="pubmed">24153252</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>